{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:56Z","timestamp":1792289516989,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.intimp.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T08:47:10Z","timestamp":1510130830000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Evaluation of the efficacy and safety of \u03b2-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I\/II clinical trial"],"prefix":"10.1016","volume":"54","author":[{"given":"Mohammad Javad","family":"Fattahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Vojdanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Saeed","family":"Yekaninejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Jafarnezhad-Ansariha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd H.A.","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Naser","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Aghazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2017.11.003_bb0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/TACG.S37325","article-title":"The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis","volume":"7","author":"Tsui","year":"2014","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.intimp.2017.11.003_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.CNE.0000413300.35194.01","article-title":"Ankylosing spondylitis: review of pathogenesis, clinical features, neurologic complications, and treatment","volume":"34","author":"Broc","year":"2012","journal-title":"Contemp. Neurosurg."},{"key":"10.1016\/j.intimp.2017.11.003_bb0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/etm.2014.2046","article-title":"T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis","volume":"9","author":"Wang","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2017.11.003_bb0020","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2017.11.003_bb0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","volume":"48","author":"Raychaudhuri","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2017.11.003_bb0030","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/rheumatology\/kev218","article-title":"Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis","volume":"54","author":"Kenna","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2017.11.003_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: current concepts in pathogenesis","volume":"15","author":"Smith","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.intimp.2017.11.003_bb0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2017.11.003_bb0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2006.08.003","volume":"36","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2017.11.003_bb0050","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2017.11.003_bb0055","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2017.11.003_bb0060","series-title":"Therapeutic Advances in Musculoskeletal Disease","first-page":"45","article-title":"Axial spondyloarthritis: is there a treatment of choice?","volume":"5","author":"Poddubnyy","year":"2013"},{"key":"10.1016\/j.intimp.2017.11.003_bb0065","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","article-title":"Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials","volume":"75","author":"Wang","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2017.11.003_bb0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08923973.2015.1113296","article-title":"Preclinical assessment of \u03b2-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug","volume":"37","author":"Fattahi","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/08923970701282387","article-title":"Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis","volume":"29","author":"Mirshafiey","year":"2007","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.etap.2007.02.002","article-title":"Production of M2000 (beta-d-mannuronic acid) and its therapeutic effect on experimental nephritis","volume":"24","author":"Mirshafiey","year":"2007","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0085","first-page":"153","article-title":"M2000: a revolution in pharmacology","volume":"11","author":"Mirshafiey","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.intimp.2017.11.003_bb0090","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1081\/IPH-200042362","article-title":"M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis","volume":"26","author":"Mirshafiey","year":"2004","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/sji.12519","article-title":"M2000 (\u03b2-d-mannuronic acid) as a novel antagonist for blocking the TLR2 and TLR4 downstream signaling pathway","volume":"85","author":"Aletaha","year":"2017","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0100","first-page":"19","article-title":"Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis","volume":"7","author":"Nicknam","year":"2008","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0105","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2014a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2017.11.003_bb0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2017.11.003_bb0115","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two\u2013week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2017.11.003_bb0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cyclooxygenase 2\u2013specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2017.11.003_bb0125","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2017.11.003_bb0130","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691730423X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691730423X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T20:42:16Z","timestamp":1538685736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757691730423X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":26,"alternative-id":["S156757691730423X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732266870.793550513","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy and safety of \u03b2-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I\/II clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}